Lishing Group
Total Page:16
File Type:pdf, Size:1020Kb
PEOPLE Inpharmatica (London) has appointed and chief scientific officer. Dr. Johnson was Andrew Ayscough as director of chemistry. previously vice president, research and devel- Dr. Ayscough was previously director of opment, and chief scientific officer at research at British Biotech Pharmaceuticals. EpiGenX Pharmaceuticals. In addition, the company has announced that a team of seven medicinal chemists has been Argenta Discovery (Harlow, UK) has recruited from Millennium Pharmaceuticals. announced the appointment of Richard The team will be based at Inpharmatica’s Lingard as vice president, business develop- recently acquired Cambridge, UK, facility. ment. He was previously director of business development at Inpharmatica. Active Pass Pharmaceuticals (Vancouver, BC, Canada) has announced that Rod Campbell Five Prime Therapeutics (S. San Francisco, is leaving his position as CFO to pursue other CA, USA) has named Gail J. Maderis presi- opportunities. Concurrent with his depar- dent and CEO. Ms. Maderis was previously ture, Jeff Tomlinson has been appointed corporate vice president of Genzyme and chief business officer. Mr. Tomlinson served president of Genzyme Molecular Oncology. as director of strategic marketing and busi- She is a member of the advisory board of the ness development at Gene Logic, and in 2001, Harvard Business School Alumni moved to GrowthWorks Capital, where he Biotechnology Roundtable, and previously was vice president of investments. served on the board of directors of the New York Pharma Forum and the scientific ad- Resverlogix (Calgary, Alberta, Canada) has visory board of the Canadian Medical appointed William A. Cochrane chairman of Discoveries Funds. Lewis T. Williams, the its board of directors. A board member since founder of Five Prime Therapeutics, will con- http://www.nature.com/naturebiotechnology May 2002, Dr. Cochrane is a former president tinue in his role as executive chairman and as of the University of Calgary, and has served leader of the company’s research efforts. as CEO and chairman of Connaught Laboratories and Stressgen Biotechnologies. Sean Marett has been named vice president He currently serves on the boards of of business development and a member of Oncolytics Biotech, Andre’s Wines, the board at Lorantis (Cambridge, UK). He Pheromone Sciences, Nucleus Bio Sciences, joins the company from Evotec OAI, where Medicure and Fox Energy. he served as chief business officer. Mark Egerton has joined Oxagen (Abingdon, ARIAD Pharmaceuticals (Cambridge, MA, UK) as chief commercial officer and a mem- USA) has announced that Paul J. Sekhri,for- ber of the board. His most recent position mer senior vice president in the global busi- was CEO of Cyprotex, and he also served as ness development and licensing group at © Group 2003 Nature Publishing vice president of European business opera- Novartis Pharma, has been appointed to the tions for Incyte. newly created position of president and chief business officer. Most recently, he was a part- The Biotechnology Industry Organization ner at the Sprout Group, the venture capital (BIO; Washington, DC, USA) has named arm of Credit Suisse First Boston. ARIAD has Barbara Glenn director of animal biotechnol- also named Athanase Lavidas,chairman and ogy and Hannah Highfill director for interna- CEO of the Lavipharm Group, to its board of tional market access. Additionally, Michael J. directors. Finally, the following promotions Phillips has been promoted to vice president, have been announced: Timothy Clackson is food and agriculture, science and regulatory ARIAD’s new chief scientific officer, John policy. Dr. Glenn comes to BIO from the Iuliucci has been named chief development Federation of Animal Science Societies, where officer, and Tomi Sawyer has been promoted she served as executive vice president and to senior vice president, drug discovery. chief scientific advisor. Ms. Highfill served most recently as the manager of international Microscience (Berkshire, biotechnology education at the US Grains UK) has appointed John Council, and previously as a legislative corre- St. Clair Roberts as spondent for US Senator Max Baucus (D- medical director and as MT). Dr. Phillips most recently served as a member of the board BIO’s executive director, food and agriculture. of directors. Dr. St. Clair Roberts previously held Paul H. Johnson has joined Nastech the same positions at Pharmaceutical (Bothell, WA, USA) as senior Xenova, and he served vice president, research and development, as medical director at Cantab. NATURE BIOTECHNOLOGY VOLUME 21 NUMBER 11 NOVEMBER 2003 1401.